Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 48 full-time employees. The firm is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. The company is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The firm is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.